<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14(1)</volume><submitter>Di Staso R</submitter><funding>Università di Bologna (University of Bologna)</funding><journal>Blood cancer journal</journal><pagination>197</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11544145</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma.</pubmed_title><pmcid>PMC11544145</pmcid><funding_grant_id>ALMAIDEA2022CUP:J33C22001420001</funding_grant_id><pubmed_authors>Casadei B</pubmed_authors><pubmed_authors>Iacoboni G</pubmed_authors><pubmed_authors>Locke FL</pubmed_authors><pubmed_authors>Bailen R</pubmed_authors><pubmed_authors>Houot R</pubmed_authors><pubmed_authors>Voorhees TJ</pubmed_authors><pubmed_authors>Di Staso R</pubmed_authors><pubmed_authors>Mian A</pubmed_authors><pubmed_authors>Terol MJ</pubmed_authors><pubmed_authors>Masetti R</pubmed_authors><pubmed_authors>Hill B</pubmed_authors><pubmed_authors>Argnani L</pubmed_authors><pubmed_authors>Kittai AS</pubmed_authors><pubmed_authors>Reguera-Ortega JL</pubmed_authors><pubmed_authors>Gori D</pubmed_authors><pubmed_authors>Broccoli A</pubmed_authors><pubmed_authors>Bachy E</pubmed_authors><pubmed_authors>Morschhauser F</pubmed_authors><pubmed_authors>Martin Garcia-Sancho A</pubmed_authors><pubmed_authors>Le Gouill S</pubmed_authors><pubmed_authors>Bastos-Oreiro M</pubmed_authors><pubmed_authors>Kwon M</pubmed_authors><pubmed_authors>Jain M</pubmed_authors><pubmed_authors>Gutierrez A</pubmed_authors><pubmed_authors>Mead M</pubmed_authors><pubmed_authors>Thieblemont C</pubmed_authors><pubmed_authors>Maranzano MJ</pubmed_authors><pubmed_authors>Barba P</pubmed_authors><pubmed_authors>Zinzani PL</pubmed_authors></additional><is_claimable>false</is_claimable><name>Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma.</name><description/><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Nov</publication><modification>2025-04-04T02:09:29.757Z</modification><creation>2025-04-04T02:09:29.757Z</creation></dates><accession>S-EPMC11544145</accession><cross_references><pubmed>39511146</pubmed><doi>10.1038/s41408-024-01183-8</doi></cross_references></HashMap>